Lexicon Pharmaceuticals Inc said its experimental drug to treat diabetes reduced the use of insulin at meal times in a mid-stage study of patients with type 1 diabetes, sending the company’s shares up as much as 17 percent. Read more
from DiabetesNews http://ift.tt/1qCTwDw
from DiabetesNews http://ift.tt/1qCTwDw